Prolonged survival without progression under crizotinib treatment.

Area of Science:

• Oncology
• Medical Genetics

Background:

• Metastatic lung adenocarcinoma treatment relies on identifying driver mutations.
• EML4-ALK rearrangement is a key mutation in a subset of non-small cell lung cancer patients.
• Crizotinib is a targeted therapy option for patients with EML4-ALK rearrangements.

Observation:

• This case study focuses on a patient with Stage-4 metastatic lung adenocarcinoma.
• The patient had undergone two surgeries and two cycles of cisplatin-based adjuvant chemotherapy.
• The patient experienced a second relapse, necessitating a change in treatment strategy.

Findings:

• Crizotinib treatment was initiated for the patient with EML4-ALK rearrangement.
• The patient achieved a 53-month remission period.
• This demonstrates the potential long-term efficacy of crizotinib in select lung cancer patients.

Implications:

• Targeted therapies like crizotinib can lead to durable responses in specific lung cancer subtypes.
• Personalized medicine approaches based on molecular profiling are crucial for optimizing treatment outcomes.
• Further research into long-term outcomes of targeted therapies is warranted.